Business
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims titled "Purine Compounds
About this update from Marvell Technology, Inc.
[{"type":"text","content":"Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims titled "Purine Compounds for Treating Disorders."","length":555,"tagName":"p"},{"type":"text","content":""This is the third major jurisdiction that has granted us a composition of matter patent for our lead molecule MB-204," commented Marvel's CEO, Rod Matheson. "We are very pleased to be granted this patent in the US, which is critical to executing our business development goals. Strong intellectual property is one of those key components pharmaceutical partners want to see when looking to consecrate a deal with a company such as Marvel."","length":464,"tagName":"p"},{"type":"text","content":"The issuance of a U.S. composition of matter patent represents a critical milestone for Marvel, marking the third patent issuance following Japan and China jurisdictions (refer to the Company's press releases dated February 3, 2026 and August 18, 2025), as it significantly strengthens the IP protection surrounding MB-204. Composition of matter claims are widely regarded as the strongest form of pharmaceutical patent protection, providing the potential for long-term market exclusivity once the compound reaches commercialization. This third patent issuance meaningfully enhances the strategic and economic value of the Company's lead asset and supports Marvel's broader strategy of advancing differentiated therapeutics with foundational intellectual property positions, creating a defensible platform asset that could underpin future clinical development, partnerships, licensing, and long-term shareholder value creation.","length":939,"tagName":"p"},{"type":"text","content":"MB-204 is a novel fluorinated analogue of the approved adenosine A2A receptor antagonist Istradefylline which is used for the treatment of Parkinson's Disease. MB-204 has demonstrated superior pharmacokinetics and completed pre-clinical tox...